US Patent 8,753,679: Pirfenidone Capsule Claims, Patent Scope, Orange Book Status, and Generic Entry Risk

US Patent No. 8,753,679 protects stable oral capsule formulations of pirfenidone, also known as 5-methyl-1-phenyl-2-(1H)-pyridone. Its core protection is a capsule containing pirfenidone and excipients that satisfies defined dissolution and stability thresholds. The patent also covers wet-granulated formulations, povidone-containing compositions, specified excipient ranges, and treatment of fibrotic and cytokine-mediated disorders using the protected capsule.

The patent is associated with InterMune, Inc., whose pirfenidone assets were acquired by Roche through Genentech. The patent is relevant to Esbriet, the FDA-approved pirfenidone product for idiopathic pulmonary fibrosis.

What does US Patent 8,753,679 protect?

The patent protects a drug product defined by three principal elements:

A capsule dosage form.
Pirfenidone with pharmaceutically acceptable excipients.
Stability demonstrated by dissolution testing after defined storage conditions.

The independent claims are claims 1, 11, and 26.

Claim	Category	Principal limitation
1	Product	Capsule with pirfenidone and excipients; at least 85% dissolution after 9 months at 40°C/75% RH
11	Method of treatment	Administration of the claim 1 capsule for fibrosis or cytokine-mediated disorders
26	Product	Capsule with at least 93% dissolution after 18 months at 25°C/60% RH

The patent does not claim pirfenidone as a chemical compound. It claims a formulation and dosage form with performance characteristics. A product containing pirfenidone can therefore avoid literal infringement if it does not meet the capsule, formulation, excipient, or stability limitations, although the doctrine of equivalents may remain relevant.

The patent is identified as US Patent No. 8,753,679 B2, titled "Pharmaceutical compositions of pirfenidone." The patent issued June 17, 2014, from an application claiming priority to an earlier US filing associated with InterMune's pirfenidone development program (USPTO, 2014).

How do the independent claims define the patent scope?

Claim 1: nine-month accelerated stability formulation

Claim 1 requires:

A capsule;
A pharmaceutical formulation;
Pirfenidone;
Pharmaceutically acceptable excipients; and
At least 85% dissolution after at least nine months at 40°C and 75% relative humidity.

The stability limitation is central. The claim is not satisfied merely because a capsule contains pirfenidone and conventional excipients. The accused product must also meet the specified dissolution result under the stated storage conditions.

The claim does not require a particular pirfenidone dose, specific capsule shell, manufacturing process, or particular excipient combination. Claims 2 through 10 narrow that broad structure.

Claim 11: treatment using the protected capsule

Claim 11 covers treating a fibrotic condition or inhibiting cytokine activity by administering the capsule of claim 1. Because it depends on claim 1, the method claim incorporates the product and stability limitations of claim 1.

This creates an important enforcement issue. A method-of-use claim may be difficult to assert against a generic product when the generic label omits the patented indication or expressly carves out a patented use. The product claim in claim 1 is therefore commercially more significant than claim 11 for ordinary ANDA litigation.

Claim 26: long-term stability formulation

Claim 26 is an independent product claim requiring:

A capsule;
Pirfenidone and pharmaceutically acceptable excipients; and
At least 93% dissolution after at least 18 months at 25°C and 60% relative humidity.

Claim 26 is materially different from claim 1. Claim 1 uses an accelerated condition, 40°C/75% relative humidity, for at least nine months. Claim 26 uses a long-term condition, 25°C/60% relative humidity, for at least 18 months.

A formulation could satisfy one claim and not the other. Stability data, analytical methods, batch records, and regulatory specifications would be central to infringement analysis.

What formulations are protected by US 8,753,679?

The dependent claims create a layered formulation estate.

Claim group	Protected subject matter
Claims 2-6	Disintegrators, binders, fillers, and lubricants
Claim 7	Quantitative excipient ranges
Claims 8-10	Povidone-containing formulations, including 100-400 mg pirfenidone
Claims 20-21	Povidone at least about 1.85% or at least about 1% by weight
Claims 22-23	Wet-granulated formulations
Claim 24	70-95% pirfenidone and 5-30% excipients
Claims 25-26	Pulmonary fibrosis use and long-term stability

Excipients and formulation architecture

Claim 3 lists a broad group of disintegrators, including croscarmellose sodium, crospovidone, sodium starch glycolate, starch, cellulose derivatives, alginates, and related materials.

Claim 4 identifies binders, including:

Microcrystalline cellulose;
Hydroxymethyl cellulose;
Hydroxypropylcellulose; and
Polyvinylpyrrolidone, also called povidone.

Claim 5 covers a broad filler group, including lactose, cellulose, calcium phosphate, starch, sucrose, sorbitol, mannitol, and related materials.

Claim 6 covers lubricants such as magnesium stearate, stearic acid, talc, sodium lauryl sulfate, and zinc stearate.

The lists are open-ended in practical claim construction because the claims use "comprising." A formulation can include additional excipients and still fall within the claims if all required limitations are present.

Quantitative excipient limitations

Claim 7 requires:

Disintegrator: 2-10% by weight;
Binder: 2-30%;
Filler: 2-30%; and
Lubricant: 0.3-0.8%.

Claim 24 provides a separate formulation profile:

Pirfenidone: 70-95% by weight;
Excipients: 5-30% by weight.

These ranges materially narrow the claims but remain broad enough to cover many conventional immediate-release hard capsules.

Povidone and wet granulation

Claims 8-10 and 20-23 focus on povidone and wet granulation. Claim 23 is particularly important because it combines:

A lubricant, filler, and disintegrator;
Microcrystalline cellulose and povidone as binders;
Povidone at 1-4%;
Total binder at 2-30%; and
A wet-granulated mixture containing pirfenidone, binder, filler, and disintegrator.

A generic manufacturer using a materially different dry-blending or direct-compression process may have a stronger noninfringement position against claim 23, even if its finished capsule meets claim 1 or claim 26.

How broad are the method-of-use claims?

Claims 11-19 and 25 cover treatment of fibrotic conditions and disorders associated with specified cytokines.

The claimed fibrotic diseases include:

Idiopathic pulmonary fibrosis;
Hermansky-Pudlak syndrome;
Hepatic fibrosis;
Cardiac fibrosis;
Scleroderma with pulmonary fibrosis;
Keloid;
Dermal fibrosis;
Coronary restenosis; and
Post-surgical adhesions.

The cytokine-related claims identify TNF-alpha, TGF-beta1, bFGF, PDGF, and EGF. The claimed disorders include multiple sclerosis, arthritis, asthma, chronic rhinitis, and edema.

Claim 17 adds a total daily pirfenidone intake of at least 1,200 mg. Claims 18 and 19 specify dosing frequency. The claims contain drafting tension because claim 19 depends through claim 18 but recites administration three times daily after claim 18 recites twice daily. That inconsistency could affect claim construction and prosecution-history analysis.

The FDA-approved Esbriet dosing regimen is generally titrated to 801 mg three times daily, or 2,403 mg per day, after an initial escalation period (FDA, 2023). The dosing limitations in the patent therefore overlap with the commercial product's labeled regimen.

When does US Patent 8,753,679 expire?

The patent's expected ordinary term runs to approximately December 2027, based on the underlying filing chronology and the 20-year patent-term framework. The controlling date for commercial planning is the expiration date shown in the current USPTO Patent Center record and FDA Orange Book listing, including any patent-term adjustment or disclaimer.

Event	Date or period
Underlying priority and filing activity	December 2007-era pirfenidone formulation filings
Patent grant	June 17, 2014
Expected ordinary expiration	Approximately December 2027
Product relevance	Esbriet pirfenidone capsules and related generic ANDA products

Patent expiration does not necessarily equal immediate generic launch. ANDA litigation, settlement terms, pediatric exclusivity, regulatory approval timing, and other listed patents can control actual entry.

What is the Orange Book status of US 8,753,679?

US 8,753,679 is associated with the Esbriet regulatory product and has been treated as an Orange Book-relevant formulation patent for pirfenidone capsules. The relevant regulatory product is Esbriet, NDA 208081, held by Genentech, Inc., a member of the Roche group.

The patent's commercial significance arises from the interaction between:

FDA approval of pirfenidone for idiopathic pulmonary fibrosis;
The capsule formulation used for the reference product;
Orange Book patent listing;
ANDA certification requirements; and
Paragraph IV litigation under the Hatch-Waxman Act.

The Orange Book listing should be read together with other patents listed for Esbriet. A generic applicant must address each applicable listed patent, not only US 8,753,679.

Which companies have challenged the Esbriet patent estate?

Pirfenidone has attracted generic development because the active ingredient itself is old and the principal barriers are formulation, regulatory, and patent-related. Generic companies have pursued ANDA approvals for pirfenidone capsules and tablets, creating potential Paragraph IV exposure for listed Esbriet patents.

Publicly identified generic competitors in the US pirfenidone market and development landscape have included companies such as Teva, Cipla, Torrent, and Aurobindo-affiliated applicants. The relevant legal question is applicant-specific: each ANDA filer may challenge different claims, use a Paragraph III certification, or seek a later entry date under a settlement.

A Paragraph IV certification does not itself invalidate the patent. It creates a statutory act of infringement and permits the patent owner to sue. A timely suit can trigger a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court action.

What patent litigation and settlement risks affect generic launch?

The main litigation risks are:

Product claim infringement based on capsule composition and stability.
Method-of-use infringement based on the label and prescribing information.
Validity attacks based on obviousness, written description, enablement, indefiniteness, and anticipation.
Disputes over whether stability limitations are inherent or require actual testing.
Claim-construction disputes over "stable," "dissolution," "formulation," and "wet-granulated mixture."

A generic applicant may pursue several strategies:

Strategy	Potential effect
Paragraph III certification	Delays launch until patent expiration
Paragraph IV certification	Creates litigation risk but may support earlier entry
Section viii carve-out	Removes patented indication from label
Different excipient system	Reduces risk under dependent formulation claims
Different manufacturing process	Targets wet-granulation claims
Non-capsule dosage form	May avoid capsule-specific product claims
Alternative dissolution profile	May avoid performance-defined claims, subject to regulatory feasibility

Settlement agreements can provide an authorized or licensed launch date before patent expiration. The commercial result depends on the negotiated date, whether the agreement includes an authorized generic, and whether the settlement covers all relevant Esbriet patents.

How strong is the patent estate for pirfenidone?

US 8,753,679 is strongest against a generic that closely copies the reference product's capsule architecture, excipient system, wet-granulation process, and stability profile.

Its principal strengths are:

Independent product claims;
Objective dissolution thresholds;
Multiple stability conditions;
Dependent claims covering common excipients;
Povidone and microcrystalline cellulose limitations;
Wet-granulation claims; and
Claims aligned with the commercial pirfenidone capsule.

Its limitations are equally important:

Pirfenidone itself is not claimed;
The claims are limited to capsules;
Stability limitations require technical proof;
Many excipient claims use conventional pharmaceutical ingredients;
A generic may design around the claimed excipient ranges;
Method claims may be narrowed by label carve-outs; and
Product claims may face obviousness arguments based on known pirfenidone formulations and routine stability optimization.

The patent is therefore a meaningful formulation barrier, but it is not a complete compound monopoly or an absolute block on every pirfenidone dosage form.

How does US 8,753,679 compare with compound and use patents?

Patent type	Protection	Relevance to pirfenidone generic entry
Compound patent	Pirfenidone molecule	Generally expired or not the principal current barrier
Formulation patent	Capsule composition and stability	Directly relevant to US 8,753,679
Method-of-use patent	Fibrotic diseases and cytokine disorders	Relevant to labeling and induced-infringement risk
Manufacturing patent	Granulation, blending, or process controls	Relevant where the generic copies the process
Regulatory exclusivity	FDA orphan-drug or pediatric exclusivity	Can delay approval independently of patent term

Pirfenidone is a small molecule. Biosimilar risk is therefore inapplicable. The competitive threat comes from conventional ANDA generics, not biosimilars.

What is the commercial exposure from generic entry?

Esbriet generated substantial commercial value for Roche and Genentech before generic competition. US revenue exposure is concentrated in:

Idiopathic pulmonary fibrosis treatment;
Long-term chronic therapy;
The 267 mg capsule presentation;
High daily capsule consumption; and
Reimbursement-sensitive specialty pharmacy distribution.

The standard maintenance regimen of 2,403 mg per day requires nine 267 mg capsules daily. A generic entrant can therefore compete on a high-volume chronic-use product, even if it initially launches with limited manufacturing capacity.

Generic entry would likely pressure:

Net price;
Specialty-pharmacy contracting;
Payer formulary position;
Patient-support economics;
Market share;
International pricing references; and
Revenue from the US IPF franchise.

What geographic coverage does US 8,753,679 provide?

US 8,753,679 provides protection only in the United States. It does not directly block manufacture, sale, or use outside the US.

International protection depends on separate national patents and patent families. Relevant jurisdictions include Europe, Canada, Japan, China, Australia, and other markets where pirfenidone is approved or commercially supplied. A US patent cannot independently prevent a foreign manufacturer from producing pirfenidone outside the US, although importing an infringing product into the US can create US patent exposure.

What manufacturing and intellectual-property barriers remain?

The most important manufacturing barrier is the need to achieve acceptable pirfenidone dissolution and stability in a high-drug-load capsule. Claims 22 and 23 increase risk for manufacturers using wet granulation with microcrystalline cellulose and povidone.

A design-around program would typically focus on:

Direct compression or dry granulation;
Alternative binders;
Different disintegrators;
Non-povidone formulations;
Different pirfenidone-to-excipient ratios;
Alternative capsule presentations;
Modified-release or other dosage forms, if regulatorily acceptable; and
Stability profiles that do not satisfy the claimed thresholds.

A design-around must account for both literal infringement and potential equivalents. It also must satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, content uniformity, dissolution, impurities, and stability.

Key Takeaways

US 8,753,679 is a pirfenidone formulation patent, not a compound patent.
Claim 1 protects capsules meeting a nine-month accelerated stability and dissolution test.
Claim 26 protects capsules meeting an 18-month long-term stability and dissolution test.
Claims 7, 8-10, 20-23, and 24 create additional protection for excipient ranges, povidone, wet granulation, and high-pirfenidone formulations.
Method claims cover pulmonary fibrosis, idiopathic pulmonary fibrosis, scleroderma-associated pulmonary fibrosis, and other fibrotic or cytokine-mediated disorders.
The patent's expected ordinary expiration is approximately December 2027, subject to the official patent-term record.
Generic risk is highest for products copying the Esbriet capsule's excipients, wet-granulation process, and dissolution profile.
Pirfenidone has no biosimilar issue because it is a small-molecule drug.
Paragraph IV challenges, Orange Book listings, settlements, pediatric exclusivity, and other Esbriet patents can alter the practical launch date.
The strongest design-around options involve changing the dosage form, excipient system, manufacturing process, or formulation percentages while preserving bioequivalence.

FAQs About US Patent 8,753,679 and Pirfenidone

Does US 8,753,679 cover all pirfenidone products?

No. It covers specified capsules and methods using those capsules. It does not claim pirfenidone as a molecule or automatically cover every tablet, solution, suspension, or other dosage form.

Can a generic avoid the patent by using different excipients?

Potentially. A different excipient system may avoid dependent claims, but the generic must still assess the independent capsule and stability claims.

Does a Paragraph IV certification invalidate US 8,753,679?

No. It alleges that the patent is invalid, unenforceable, or not infringed. A court decision or settlement determines the practical result.

Are the claim 1 and claim 26 stability tests interchangeable?

No. Claim 1 uses nine months at 40°C/75% relative humidity and at least 85% dissolution. Claim 26 uses 18 months at 25°C/60% relative humidity and at least 93% dissolution.

Can a generic launch before patent expiration?

It can launch before expiration only if it obtains a successful litigation outcome, reaches a settlement permitting earlier entry, receives an authorized launch arrangement, or otherwise avoids the applicable patent and regulatory barriers.

References

U.S. Food and Drug Administration. (2023). Esbriet (pirfenidone) prescribing information. Genentech, Inc.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,753,679 B2: Pharmaceutical compositions of pirfenidone. Washington, DC.
U.S. Food and Drug Administration. (2024). Drugs@FDA: Esbriet, NDA 208081. Center for Drug Evaluation and Research.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Legacy	ESBRIET	pirfenidone	CAPSULE;ORAL	022535-001	Oct 15, 2014	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	2655	⤷ Start Trial
Australia	2006295440	⤷ Start Trial
Australia	2011201520	⤷ Start Trial
Australia	2013201986	⤷ Start Trial
Australia	2014240300	⤷ Start Trial
Brazil	PI0616324	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,753,679

Which drugs does patent 8,753,679 protect, and when does it expire?

Summary for Patent: 8,753,679